Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Mantle-Cell 39Waldenstrom Macroglobulinemia 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 14Recurrence 10Lymphoma, B-Cell, Marginal Zone 10Leukemia 9Lymphoma, B-Cell 8Lymphoma 8Neoplasms 7Lymphoma, Non-Hodgkin 5Leukemia, Prolymphocytic 4Hodgkin Disease 4Multiple Myeloma 3Leukemia, Myeloid, Acute 3Leukemia, B-Cell 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Glioblastoma 2Chromosome 17 deletion 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Primary Central Nervous System Lymphoma (PCNSL) 1

Interventions

ibrutinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Central Nervous System Lymphoma (PCNSL) × ibrutinib × Clear all
NCT07082868 2026-05-06

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
26 enrolled
CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡